NCT06738082View on ClinicalTrials.gov

Influenza Vaccine Elicited Immune Response in Immunocompromised Patients

CompletedOBSERVATIONAL
Enrollment

147

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Influenza VaccineImmunocompromised Patients
Interventions
BIOLOGICAL

Influenza vaccine

Standard, commercially available, quadrivalent split-vaccine against influenza is given to all study participants.

Trial Locations (1)

3010

Universitsy Hospital Bern, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT06738082 - Influenza Vaccine Elicited Immune Response in Immunocompromised Patients | Biotech Hunter | Biotech Hunter